Back to search
FDAFDA · Food and drugs·Recall number Z-2448-2018

PROLENE SUTURE MONO BLUE - BV1755 Taper Point 3/8C, D10031

Published July 25, 2018 · Recall initiated: May 7, 2018

Summary

FDA records medical device Class II recall Z-2448-2018, published July 25, 2018 and initiated May 7, 2018. Recalling firm: Ethicon, Inc.; Status: Terminated; Reported quantity: 1752; Lot: KDJ805 KDP827 LBB354 MAP602. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

The needle associated with certain suture product codes has the potential to perforate the packaging due to a packaging design issue. A perforated package has the potential to cause a soft tissue injury to a healthcare professional handling the subject product or a patient infection due to a breach of sterility within the packaging if it goes unnoticed by the healthcare professional.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Ethicon, Inc.
Distributor
Accounts in AZ, CA, CO, FL, GA, IL, IN, KS, MA, MN, MO, NC, NE, NJ, NY, OH, OR, SC, SD, TN, TX, VA, WA, WI, WV.
Lot
KDJ805 KDP827 LBB354 MAP602
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was PROLENE SUTURE MONO BLUE - BV1755 Taper Point 3/8C, D10031 recalled?

Yes. FDA published recall Z-2448-2018 on July 25, 2018. Reported hazard: The needle associated with certain suture product codes has the potential to perforate the packaging due to a packaging design issue. A perforated package has the potential to cause a soft tissue injury to a healthcare professional handling the subject product or a patient infection due to a breach of sterility within the packaging if it goes unnoticed by the healthcare professional.

What should I do if I have this product?

Voluntary: Firm initiated · Letter